InterCure

About

InterCure is a medical device company focused on respiratory treatment that has developed and patented a technology platform.

Ra'anana,HaMerkaz,Israel
51 - 100

Highlights

Details

Last Funding Type: Post-IPO Equity
Last Funding Money Raised: $17.50M
Industries: Biotechnology,Health Care,Manufacturing,Medical Device,Therapeutics
Founded date: Jan 1, 1994
Number Of Employee: 51 - 100
Operating Status: Active
Stock Symbol: tlv:INCR
Legal Name: InterCure Ltd

InterCure is a medical device company that has developed and patented a technology platform for respiratory-based treatment of cardiovascular and pulmonary diseases.

The Company has incorporated its "Interactive Respiratory-Pacing" technology platform into several product lines, the first two of which offer a new therapeutic class of non-drug treatments for two of the most widespread and costly disease states in the healthcare industry: hypertension and heart failure.

InterCure’s first market-ready product, RESPeRATE, is the only FDA-cleared, medical device clinically proven to lower high blood pressure with no side effects.

InterCure's heart failure product, InTone™ has successfully completed phase 2a efficacy clinical trials and is expected to be launched when it completes the regulatory approval process.

With its outstanding management team, the board of directors and a world-class Scientific Advisory Board, Intercure is poised to become the market leader in patient-focused medical devices that provide non-drug, no-side-effect treatment for some of the world's most prevalent and costly chronic conditions.

InterCure was founded in 1994 and is headquartered in Ra'anana, Israel.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

7

$41.90M

InterCure has raised a total of $41.90M in funding over 2 rounds. Their latest funding was raised on Feb 11, 2021 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Feb 11, 2021	Post-IPO Equity	$8M	1	ARK Investment Management	—	Detail
Nov 1, 2018	Post-IPO Equity	$17.50M	2	GMF Capital	—	Detail
Oct 27, 2011	IPO	—	—	—	—	Detail
Apr 13, 2005	Series C	$3M	2	—	—	Detail
Oct 30, 2001	Series B	$4.50M	6	Medica Venture Partners	—	Detail

Investments

Number of Investments

Number of Lead Investments

1

InterCure has made 1 investments. Their most recent investment was on Dec 23, 2015, when Fore Biotherapeutics raised $10M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Dec 23, 2015 Fore Biotherapeutics	Series Unknown	$10M	Biotechnology	Yes

Investors

Number of Lead Investors

Number of Investors

3

12

InterCure is funded by 12 investors. ARK Investment Management and GMF Capital are the most recent investors.

Investor Name	Lead Investor	Funding Round
ARK Investment Management	Yes	Post-IPO Equity
GMF Capital	Yes	Post-IPO Equity
Adam Neumann	—	Post-IPO Equity
Medica Venture Partners	—	Series C
Nippon Venture Capital	—	Series C
Arie Ovadia	—	Series B
Daniel Plotkin	—	Series B
Mizrahi Tefahot Bank	—	Series B
Palladin Consumer Retail Partners	—	Series B
True North Partners	—	Series B